MYGN - Myriad Genetics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
29.08
+0.65 (+2.27%)
As of 3:12PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close28.43
Open28.73
Bid29.05 x 800
Ask29.08 x 3200
Day's Range28.65 - 29.24
52 Week Range20.10 - 48.40
Volume282,456
Avg. Volume1,046,482
Market Cap2.163B
Beta (5Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)-0.21
Earnings DateFeb 02, 2020 - Feb 06, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.38
  • Earnings Preview: Myriad Genetics (MYGN) Q2 Earnings Expected to Decline
    Zacks

    Earnings Preview: Myriad Genetics (MYGN) Q2 Earnings Expected to Decline

    Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer

    Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) for its myChoice® CDx test to help predict outcomes of women with first-line platinum responsive advanced ovarian cancer treated with GSK’s PARP inhibitor Zejula® (niraparib). “The myChoice CDx test provides valuable molecular insights into tumors and helps identify women with ovarian cancer who are most likely to benefit from PARP inhibitors,” said Nicole Lambert, president, Myriad Oncology.

  • GlobeNewswire

    Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prostate Cancer

    Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced today that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) for its BRACAnalysis® CDx test as a companion diagnostic to AstraZeneca’s (LSE/OMX Nordic/NYSE: AZN) and Merck’s PARP inhibitor Lynparza® (olaparib) for men with metastatic castration-resistant prostate cancer.

  • GlobeNewswire

    Dr. Thomas P. Slavin Named Senior Vice President of Medical Affairs for Myriad Oncology

    Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced that it has named Thomas P. Slavin, M.D., FACMG, DABMD, senior vice president of Medical Affairs at Myriad Oncology effective March 2, 2020. In this role, Dr. Slavin will provide medical and scientific leadership across Myriad's portfolio of molecular and companion diagnostic products and services for oncology. Dr. Slavin will report to Nicole Lambert, president of Myriad Oncology.

  • Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging
    Zacks

    Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging

    The result of this clinical trial is a major stride forward in Myriad Genetics' (MYGN) commitment toward strengthening its portfolio of depressive disorder treatments.

  • GlobeNewswire

    Myriad Genetics to Present at the J.P. Morgan 2020 Healthcare Conference

    SALT LAKE CITY, Jan. 06, 2020 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that Mark C. Capone, president and.

  • GlobeNewswire

    New Publication Demonstrates GeneSight® Improved All Clinical Outcomes Using HAM-D6 Analysis in Large Prospective GUIDED Study

    Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new analysis of the GUIDED1 clinical trial using the 6-item Hamilton Depression Rating Scale (HAM-D6) was published online in BMC Psychiatry. The key finding is the HAM-D6 scale identified statistically significant improvements in all three clinical endpoints – remission, response and symptoms – between GeneSight®-guided care and treatment-as-usual at Week 8 (Figure 1).

  • Myriad Genetics' Cancer Companion Diagnostic Test Gets FDA Nod
    Zacks

    Myriad Genetics' Cancer Companion Diagnostic Test Gets FDA Nod

    Myriad Genetics (MYGN) expands the use of BRACAnalysis CDx as a companion diagnostic test for metastatic pancreatic cancer with the receipt of the FDA clearance.

  • This Genetic-Testing Stock Popped, Then Slipped, On Its FDA Approval
    Investor's Business Daily

    This Genetic-Testing Stock Popped, Then Slipped, On Its FDA Approval

    Shares of Myriad Genetics initially popped Monday after the Food and Drug Administration approved the company's genetic test, dubbed BRACAnalysis CDx, for pancreatic cancer patients.

  • Business Wire

    INVESTOR ALERT: Kirby McInerney LLP Launches Investigation of Myriad Genetics (MYGN) for Possible Breaches of Fiduciary Duty by Certain Officers and Directors

    The law firm of Kirby McInerney LLP is investigating potential claims against Myriad Genetics Inc. ("Myriad" or the "Company") (NASDAQ: MYGN). The investigation relates to possible breaches of fiduciary duty by certain officers and directors of the Company.

  • Barrons.com

    Nio Stock Is Soaring, Myriad Genetics Jumps, as the Dow Holds Its Ground

    Wall Street is set for a sleepy open Monday with stock futures indicating modest gains across all three indexes. The Dow Jones Industrial Average, S&P 500 and Nasdaq Compositewere all set to open up 0.1% as of 8:20 a.m. in what is expected to be a quiet day for trading. (AZN) (ticker: AZN) and (MRK) (MRK) were up 0.6% and 0.2%, respectively, after Lynparza, the ovarian-cancer drug they market, won approval by the Food and Drug Administration to be used to treat advanced pancreatic cancer.

  • MarketWatch

    Myriad Genetics's stock surges after FDA approval of diagnostic test for pancreatic cancer

    Share of Myriad Genetics Inc. shot up 8.3% in premarket trading Monday, after the molecular diagnostics company said its BRACAnalysis CDx was approved by the Food and Drug Administration as a companion test to identify patients with metastatic pancreatic cancer, who are candidates for treatment with Lynparza. BRACAnalysis CDx is the only FDA-approved genetic test for this indication. Lynparza is marketed by AstraZeneca PLC and Merck & Co. Inc. . "The approval of the BRACAnalysis CDx test for patients with pancreatic cancer highlights our shared vision and long-standing collaboration with Myriad to advance precision medicine for patients in need of new treatments," said Ruth March, head of precision medicine at AstraZeneca. Myriad Genetics's stock has lost 7.9% year to date through Friday, while the S&P 500 has gained 29%.

  • GlobeNewswire

    Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic Cancer

    Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® for use as a companion diagnostic test by healthcare professionals to identify patients with metastatic pancreatic cancer who have a germline BRCA mutation and are candidates for treatment with PARP inhibitor Lynparza® (olaparib). Lynparza is marketed by AstraZeneca (LSE/OMX Nordic/NYSE: AZN) and Merck, known as MSD outside of the U.S. and Canada.

  • TheStreet.com

    Myriad Genetics Spikes on FDA Approval of Pancreatic Cancer Diagnostic Test

    The Food and Drug Administration approves BRACAnalysis CDx, Myriad Genetics' metastatic pancreatic cancer diagnostic tool for patients who are eligible for treatment with Lynparaza, a drug marketed by AstraZeneca.

  • Does Myriad Genetics's (NASDAQ:MYGN) Share Price Gain of 47% Match Its Business Performance?
    Simply Wall St.

    Does Myriad Genetics's (NASDAQ:MYGN) Share Price Gain of 47% Match Its Business Performance?

    It hasn't been the best quarter for Myriad Genetics, Inc. (NASDAQ:MYGN) shareholders, since the share price has fallen...

  • Barrons.com

    Myriad Genetics Is Tumbling After The Wall Street Journal Highlighted the Risks of Acting on Genetic Testing

    Over the weekend, Myriad was the subject of a Wall Street Journal report that profiled a woman who had her ovaries and fallopian tubes removed after a genetic test showed a heightened risk of cancer. Years later, the woman learned that an updated interpretation of the lab results showed that the specific mutation may not be linked to an increase in cancer risk.

  • Hedge Funds Are Dumping Myriad Genetics, Inc. (MYGN)
    Insider Monkey

    Hedge Funds Are Dumping Myriad Genetics, Inc. (MYGN)

    Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018 as investors first worried over the possible ramifications of rising interest rates and the escalation of the trade war with China. The hedge funds and institutional investors we track […]

  • GlobeNewswire

    Myriad Genetics’ Board Member, S. Louise Phanstiel, Recognized by WomenInc. Magazine in 2019 List of Most Influential Corporate Directors

    Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced that board member S. Louise Phanstiel has been named to WomenInc. “We congratulate Louise for this well-deserved acknowledgment of her leadership and many contributions to our success,” said Mark C. Capone, president and CEO of Myriad Genetics.

  • Myriad Genetics Presents Trial Outcomes in Breast Health
    Zacks

    Myriad Genetics Presents Trial Outcomes in Breast Health

    Myriad Genetics' (MYGN) PRS enhances the detection of breast cancer risk in women having PV in high- and moderate-penetrance breast cancer genes.

  • GlobeNewswire

    Myriad’s Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes

    Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced that results of a new validation study of the company’s polygenic risk score (PRS) for breast cancer were presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Tx. The key finding is that the PRS significantly improves the precision and accuracy of breast cancer risk estimates for women of European ancestry who have pathogenic variants (PV) in high- and moderate-penetrance breast cancer genes.

  • Hedge Funds Love Tri Pointe Group Inc (TPH) Way More Than These 3 Stocks
    Insider Monkey

    Hedge Funds Love Tri Pointe Group Inc (TPH) Way More Than These 3 Stocks

    Is Tri Pointe Group Inc (NYSE:TPH) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market […]

  • Myriad Genetics Reports Favorable Study Result on Prequel
    Zacks

    Myriad Genetics Reports Favorable Study Result on Prequel

    Myriad Genetics (MYGN) posts breakthrough results on Prequel Prenatal Screen methodology, proving its superiority over traditional methods.

  • Myriad (MYGN) Up 18.4% Since Last Earnings Report: Can It Continue?
    Zacks

    Myriad (MYGN) Up 18.4% Since Last Earnings Report: Can It Continue?

    Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • MarketWatch

    Myriad shares fall despite positive results on prenatal test

    Shares of Myriad Genetics dropped 3% in premarket trading after the diagnostics maker said its Prequel prenatal screening test is better than non-DNA tests at identifying chromosomal abnormalities in pregnant women with a high body mass index. The study's results were published in the journal Prenatal Diagnosis. Myriad said that Prequel, which uses whole-genome sequencing, can help reduce the need for expensive procedures like amniocentesis or chorionic villus sampling. Sales of its prenatal business, which makes up about 12% of total revenues, rose 5% to $23.5 million in the most recent quarter, up from $18.1 million in the same period a year ago. Myriad's stock has tumbled 14% year-to-date. The S&P 500 is up 24%.

  • GlobeNewswire

    Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening

    Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new study of the Prequel™ Prenatal Screen was published online in the journal Prenatal Diagnosis. The key finding is that Prequel is superior to traditional non-DNA screening for identifying chromosomal abnormalities in pregnant women, including those with high body mass index (BMI). The Prequel Prenatal Screen uses a proprietary whole genome sequencing (WGS) approach to identify chromosomal abnormalities including trisomy 21, trisomy 18 and trisomy 13.